A Pharmacist’s Perspective on Optimizing Therapy Selection and Deprescribing in Oncology: Jason Bergsbaken, PharmD, MBA, BCOP

Jason Bergsbaken, PharmD, MBA, BCOP, explains the value of pharmacist involvement in precision molecular tumor boards and end-of-life care discussions, highlighting their role in ensuring evidence-based therapy selection, patient-specific recommendations, and shared decision-making that aligns treatment with individual goals.